Pay in 4 interest-free payments of $5.39 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Key Takeaways Mechanism of action: Triple-hormone agonist targeting GLP-1, GIP, and glucagon receptors Efficacy: 24.2% average weight loss in 48 weeks UK availability: 2026 (UK), potentially 2027 (FDA) Common side effects: Nausea, diarrhoea, vomiting, constipation Safety profile: Similar to existing GLP-1 medications but with concerns about rapid weight loss By entering I agree to the Terms and Conditions
Patients should work with healthcare providers or registered dietitians to ensure nutritional adequacy during weight loss
Some insurance providers, including Medicare, do not offer reimbursement to treat obesity alone
Approval will likely require prior authorization and step therapy
Some patients with well-controlled arrhythmias can safely use semaglutide with closer monitoring, while others may not be appropriate candidates
Keep a detailed log of cycle dates, flow intensity, and any other symptoms for at least two cycles
US$ 26.66
US$ 21.36
US$ 21.23
